Month: October 2020

Honored to present on Suprachoroidal Drug Delivery & Clearside’s preclinical and…

[ad_1] Honored to present on Suprachoroidal Drug Delivery & Clearside’s preclinical and clinical research programs at the recent Ophthalmology Futures Retina Forum… #eyes #ophthalmology #retina #macula #clinicalresearch #biotech #clinicaltrials https://t.co/5VuPYwj5hJ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinalPhys: Both Regenxbio and Aura Biosciences have recently begun new cli…

[ad_1] RT @RetinalPhys: Both Regenxbio and Aura Biosciences have recently begun new clinical trials that use Clearside Biomedical’s suprachoroidal… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

We studied anti-VEGF #outcomes in ~100,000 cases across 3 common #retina disorde…

[ad_1]
We studied anti-VEGF #outcomes in ~100,000 cases across 3 common #retina disorders. #Vision improves more in RVO-related #macula edema vs #AMD & #DME, but shows a larger gap vs corresponding randomized trials. More effective durable treatments are needed for AMD, DME, DR, & RVO. https://t.co/iA0ZHhNgsZ
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @ThomasCiullaMD: We studied anti-VEGF #outcomes in ~100,000 cases across 3 co…

[ad_1] RT @ThomasCiullaMD: We studied anti-VEGF #outcomes in ~100,000 cases across 3 common #retina disorders. #Vision improves more in RVO-relate… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

We studied anti-VEGF #outcomes in ~100,000 cases across 3 common #retina disorde…

[ad_1] We studied anti-VEGF #outcomes in ~100,000 cases across 3 common #retina disorders. #Vision improves more in RVO-related #macula edema vs #AMD & #DME, but shows a larger gap vs corresponding randomized trials. We need durable more effective #treatments! https://t.co/cTwLDeVCZc [ad_2] Source by Thomas Ciulla, 

Interviewed for this Medscape piece on Macular Degeneration Treatment Protocols …

[ad_1]
Interviewed for this Medscape piece on Macular Degeneration Treatment Protocols – more effective & longer acting treatments are needed…

Changes to Anti-VEGF Protocols Questioned in Wet AMD https://t.co/wkrCmnYctY via @medscape

#ophthalmology #retina #macula #clinicalresearch
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Congrats to the U.Iowa team for this important paper on ocular #AAV #genetherapy…

[ad_1] Congrats to the U.Iowa team for this important paper on ocular #AAV #genetherapy delivery: Retinal Tropism and Transduction of Adeno-Associated Virus (AAV) Varies by Serotype and Route of Delivery (Intravitreal, Subretinal or Suprachoroidal) in Rats https://t.co/UFRZn4h1XJ [ad_2] Source by Thomas Ciulla, MD, MBA Return 

RT @biorxiv_genetic: Host immune responses after suprachoroidal delivery of AAV8…

[ad_1] RT @biorxiv_genetic: Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes https://t.co/r2uwKfc1dV #biorxiv… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @RetinaJournal: Current Issue: SUPRACHOROIDAL INJECTION OF TRIAMCINOLONE ACET…

[ad_1]
RT @RetinaJournal: Current Issue: SUPRACHOROIDAL INJECTION OF TRIAMCINOLONE ACETONIDE, CLS-TA, FOR MACULAR EDEMA DUE TO NONINFECTIOUS UVEIT…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @TrialBulletin: RGX-314 Gene Therapy Administered in the Suprachoroidal Space…

[ad_1] RT @TrialBulletin: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Ce… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.